Kanoko Matsuyama

1 month ago | japantimes.co.jp | Hideyuki Sano |Kanoko Matsuyama

Japanese conglomerates are scaling back their hundreds of listed subsidiaries, a structure that critics say is often a poor use of capital and raises potential conflicts of interest. The trend stems from mounting pressure on companies to cater to shareholders in response to activist campaigns, demands from the stock exchange and even hostile takeovers.

1 month ago | news.bloombergtax.com | Hideyuki Sano |Kanoko Matsuyama

Japanese conglomerates are scaling back their hundreds of listed subsidiaries, a structure that critics say is often a poor use of capital and raises potential conflicts of interest. The trend stems from mounting pressure on companies to cater to shareholders in response to activist campaigns, demands from the stock exchange and even hostile takeovers.

1 month ago | bloomberg.com | Hideyuki Sano |Kanoko Matsuyama

The Nippon Telegraph and Telephone Corp. outside Otemachi First Square, which houses the company's head office, in Tokyo, Japan. (Bloomberg) -- Japanese conglomerates are scaling back their hundreds of listed subsidiaries, a structure that critics say is often a poor use of capital and raises potential conflicts of interest. The trend stems from mounting pressure on companies to cater to shareholders in response to activist campaigns, demands from the stock exchange and even hostile takeovers.

1 month ago | bloomberglinea.com | Alice French |Kanoko Matsuyama |Lisa Pham |Simon Dawson

Bloomberg — Las acciones de las empresas farmacéuticas cayeron en todo el mundo después de que el presidente de EE.UU., Donald Trump, anunciara su intención de ordenar una reducción de los costos de los medicamentos recetados en EE.UU. para equipararlos a los de otros países. Esto generó preocupación sobre el impacto en las ganancias del sector. Farmacéuticas europeas, entre ellas Novo Nordisk A/S (NVO), AstraZeneca Plc (AZN) y Roche Holding AG, se desplomaron.

1 month ago | bloomberg.com | Alice French |Kanoko Matsuyama |Lisa Pham

Las acciones de las empresas farmacéuticas cayeron en todo el mundo después de que el presidente de EE.UU., Donald Trump, anunciara su intención de ordenar una reducción de los costos de los medicamentos recetados en EE.UU. para equipararlos a los de otros países. Esto generó preocupación sobre el impacto en las ganancias del sector. Farmacéuticas europeas, entre ellas Novo Nordisk A/S, AstraZeneca Plc y Roche Holding AG, se desplomaron.